The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer
about
Molecular Targeted Therapies of Aggressive Thyroid CancerPI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasmsAutophagy in thyroid cancer: present knowledge and future perspectivesRaf kinases in cancer-roles and therapeutic opportunitiesBRAF activates and physically interacts with PAK to regulate cell motilityOxidative stress: a new risk factor for thyroid cancerOncogenic BRAF disrupts thyroid morphogenesis and function via twist expression.Apigenin in combination with Akt inhibition significantly enhances thyrotropin-stimulated radioiodide accumulation in thyroid cells.Activated leukocyte cell adhesion molecule expression and shedding in thyroid tumors.Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling.Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71.Differential expression of transforming growth factor-beta in benign vs. papillary thyroid cancer nodules; a potential diagnostic tool?Molecular pathogenesis and mechanisms of thyroid cancerNovel approaches in anaplastic thyroid cancer therapyB-RafV600E inhibits sodium iodide symporter expression via regulation of DNA methyltransferase 1Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier.Cadherin 6 is a new RUNX2 target in TGF-β signalling pathwayDisruption of mutated BRAF signaling modulates thyroid cancer phenotypeTargeted treatment of differentiated and medullary thyroid cancer.Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.The utility of BRAF testing in the management of papillary thyroid cancer.Modulation of sodium iodide symporter in thyroid cancerLate intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.Modulation of thyroidal radioiodide uptake by oncological pipeline inhibitors and ApigeninSKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancerThe Usefulness of Preoperative Thyroid-Stimulating Hormone for Predicting Differentiated Thyroid Microcarcinoma.GLI1 Transcription Factor Affects Tumor Aggressiveness in Patients With Papillary Thyroid Cancers.The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese PatientsCDKN2B Loss Promotes Progression from Benign Melanocytic Nevus to Melanoma.The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.Activated E2F activity induces cell death in papillary thyroid carcinoma K1 cells with enhanced Wnt signalingFirst-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma: A Case ReportExpression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas.Evolving approaches to patients with advanced differentiated thyroid cancerHyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells.BRAF and epithelial-mesenchymal transition in papillary thyroid carcinoma - challenging the roles of Snail and E-Cadherin?Identification of benign and malignant thyroid nodules by in vivo iodine concentration measurement using single-source dual energy CT: A retrospective diagnostic accuracy study.Long non-coding RNA ANRIL promotes the invasion and metastasis of thyroid cancer cells through TGF-β/Smad signaling pathwayDown-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer.Clinical implications of bilateral lateral cervical lymph node metastasis in papillary thyroid cancer: a risk factor for lung metastasis.
P2860
Q26774734-4E8795B7-1B7E-4833-A057-951DE7AAEEF2Q26862544-52D2812A-A96F-4EE4-A739-03233FEB431CQ28086785-6EB2D1BC-B576-4E15-866E-CA872C579A9BQ28237793-B96683A1-17E3-42F3-BC44-4C6A8EE6989BQ28248127-468C70EF-8912-445D-8C67-3EC182F9EC36Q28388902-937DE67A-6DD1-46FD-86D6-8074EFE8C07CQ33558907-F9E81486-3DFF-4CF2-BDEB-F66F7B52EE3CQ33632438-E7D5152F-5D1A-40B7-85E9-F4D56CE77446Q33833972-AC42456B-49BA-4D2B-88D9-CDDE44D6E9FAQ33839230-DF30A260-C099-4F0E-9C91-CF01267EE3C5Q33914771-A8C12D78-619A-425F-ABF0-38A8E79D3397Q33969990-D12F4AC3-18E4-4D3C-96BE-CB221EE61DE9Q34329018-77827F05-30E2-4702-83C5-6D8ADF241F9BQ34458018-C13E02F9-A50D-4686-A736-EEDC1B405146Q34669305-9A000911-BE7F-459E-A3C0-095EE835A8D0Q34975148-910C2137-AE59-45B8-B86B-B587211ED350Q34999638-1F7FBB13-5F41-4796-BB16-87B75EC329C3Q35132767-75A080AE-527F-468C-87BD-80EF0342606DQ35147151-B839742F-E48E-4071-98A3-C257471378C7Q35578577-73F27A4B-2F77-4021-869B-7A6F800DA833Q35583821-2AB18B51-D95D-4EF5-8883-5DF23C57EB17Q35690173-DFB67680-6783-47BD-ACF0-7DE7EA12C514Q35744562-2E0CD555-5EC5-4496-80B2-8E7DE3286ED3Q35784584-A9E57D71-EA48-46FF-B849-0606525EE6F1Q35803670-AA97A255-0AFB-4D99-A3EA-F6E7F088D979Q35849441-797108E7-15AF-4D89-A5C6-285003166D49Q35857790-8AA66490-90C5-49AE-B78E-791EC6B2335CQ35932262-17B49268-1A5B-479C-A143-E4DB847329BBQ36117850-01859F01-1E92-4668-A3BC-042847C41ECAQ36128415-00BFFA08-39ED-4808-B602-5B629653DDF8Q36389563-D166FCEC-07C4-4CDE-B57D-3C769AD2233FQ36565803-03ED4947-7A4C-4C26-9E79-C648BE3905D7Q36574098-BD2E299C-F7EA-4E46-A1EA-538A50E6E861Q36864736-8D8DFC1A-9D1C-416E-B250-A2890307326BQ36962376-6AD0616D-4662-4683-8045-877188F610C7Q37448258-B78D08DB-A6CE-4FB2-9B51-CE489C907047Q37605786-26375387-943D-4410-B96D-97484E579844Q37628948-FA958714-1B87-41DA-A2E4-2E0C5876D61BQ37706028-A2844B50-601A-4333-B52E-52F12449840FQ37873377-6CA0EA33-85CC-4F46-BB83-434EC16980D9
P2860
The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer
description
2009 nî lūn-bûn
@nan
2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
The BRAFV600E oncogene induces ...... d malignancy in thyroid cancer
@ast
The BRAFV600E oncogene induces ...... d malignancy in thyroid cancer
@en
The BRAFV600E oncogene induces ...... d malignancy in thyroid cancer
@nl
type
label
The BRAFV600E oncogene induces ...... d malignancy in thyroid cancer
@ast
The BRAFV600E oncogene induces ...... d malignancy in thyroid cancer
@en
The BRAFV600E oncogene induces ...... d malignancy in thyroid cancer
@nl
prefLabel
The BRAFV600E oncogene induces ...... d malignancy in thyroid cancer
@ast
The BRAFV600E oncogene induces ...... d malignancy in thyroid cancer
@en
The BRAFV600E oncogene induces ...... d malignancy in thyroid cancer
@nl
P2093
P50
P1433
P1476
The BRAFV600E oncogene induces ...... d malignancy in thyroid cancer
@en
P2093
Eugenia Costamagna
Irene Rodríguez
Manuel Nistal
Nancy Carrasco
P304
P356
10.1158/0008-5472.CAN-09-1248
P407
P577
2009-11-01T00:00:00Z